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Background: Surgery with pleurectomy/decortication (P/D) or 
extrapleural pneumonectomy (EPP) can be an option for selected 
patients with resectable malignant pleural mesothelioma (MPM). 
The aim of this study was to investigate the impact of surgical treat-
ment on the outcome of patients with MPM.
Methods: We retrospectively reviewed data from 1365 consecutive 
patients with histologically proven MPM, treated from 1982 to 2012 
in six Institutions. Patients received chemotherapy alone (n = 172), 
best supportive care (n = 690), or surgical treatment (n = 503), by 
either P/D (n = 202) or EPP (n = 301) with or without chemotherapy.
Results: After a median follow-up of 6.7 years (range, 1.1–14.8), 
230 patients (16.8%) were alive; median survival for patients who 
received palliative treatment or chemotherapy alone, P/D, and EPP 
were 11.7 (95% CI, 10.5–12.5), 20.5 (95% CI, 18.2–23.1), and 18.8 
(95% CI, 17.2–20.9) months, respectively. The 30-day mortality was 
2.6% after P/D and 4.1% after EPP (p = 0.401). According to multi-
variate analysis (n = 1227), age less than 70, epithelial histology, and 
chemotherapy were independent favorable prognostic factors. In the 
subset of 313 patients (25.5%) with all favorable prognostic factors, 
median survival was 18.6 months after medical therapy alone, 24.6 
months after P/D, and 20.9 months after EPP (p = 0.596).
Conclusions: Our data suggest that patients with good prognostic 
factors had a similar survival whether they received medical therapy 
only, P/D, or EPP. The modest benefit observed after surgery during 
medical treatment requires further investigation, and a large multi-
center, randomized trial, testing P/D after induction chemotherapy 
versus chemotherapy alone in MPM patients with good prognostic 
factors, is needed.
Key Words: Malignant pleural mesothelioma, Extrapleural pneu-
monectomy, Pleurectomy/decortication, Chemotherapy, Palliative 
treatment.
(J Thorac Oncol. 2014;9: 390–396)
Malignant pleural mesothelioma (MPM) is a rare and aggressive disease with approximately 2500 newly 
diagnosed cases each year in United States and approximately 
5000 in Western Europe.1,2 Median survival is 6 to 9 months 
from the diagnosis, and 6-month, 1-year, and 5-year overall 
survival are 55%, 33%, and 5%, respectively.3
Medical management of MPM with chemotherapy 
or radiotherapy has obtained only limited improvement 
of survival, with pemetrexed and cisplatin chemotherapy 
reaching a median survival of 12 versus 9 months with best 
supportive care.4 Surgery can be an option for patients with 
good performance status and resectable disease, by either 
pleurectomy/decortication (P/D) or extrapleural pneumonec-
tomy (EPP), but patient selection and optimal surgical strat-
egy are still controversial. The aim of surgery is to remove 
all macroscopic disease, but a complete resection without 
microresidual disease (R0) is extremely difficult to obtain. 
Therefore, surgical treatment has been combined with che-
motherapy and radiotherapy to improve local control and 
survival. Encouraging results have been reported for EPP 
combined with chemotherapy and radiotherapy, with a median 
survival ranging from 17 to 35 months.5–7 Recently, several 
studies comparing the EPP with less invasive surgical proce-
dures, such as P/D, showed similar results in terms of survival, 
with lower postoperative morbidity and mortality.8–10 The best 
treatment for the individual patient remains unknown, because 
published series are too small and heterogeneous to demon-
strate statistically significant differences in survival. In fact, 
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surgical patients selected on the basis of best prognostic fac-
tors are usually compared with nonsurgical candidates with 
the poorest prognosis.
At present, there is only one small, prospective, ran-
domized study, the Mesothelioma And Radical Surgery 
(MARS) trial, which did not show any benefit of EPP 
after chemotherapy compared with chemotherapy alone.11 
Moreover, the decision to perform either P/D or EPP is on 
the basis of surgeon’s preference rather than scientific data.
The primary aim of this retrospective, multicenter study 
was to investigate the impact of surgical treatment on the out-
come of patients with MPM, having adjusted for independent 
prognostic factors.
MATERIAL AND METHODS
We retrospectively reviewed data from 1365 consecutive 
patients with histologically proven MPM, who had undergone 
thoracoscopic or open pleural biopsy between September 1982 
and September 2012 at six Institutions (Spedali Civili Brescia, 
Ospedale Maggiore della Carità Novara, San Luigi Hospital 
Orbassano (Torino), Policlinico hospital Milan, IRCCS San 
Martino Genova, and Fondazione IRCCS Istituto Nazionale 
dei Tumori Milan; Supplemental Table, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A517). A common variable 
database was created. Clinical data were obtained from institu-
tional databases, and variables recorded included age, sex, asbes-
tos exposure, smoking history, histologic subtype, stage, surgical 
procedure, and chemotherapeutic regimens when available.
In all patients, tissue sampling was achieved by means 
of thoracoscopy (n = 1282) or open pleural biopsy (n = 83) 
under general anesthesia. In the absence of pleural effusion, 
patients underwent open pleural biopsy by lateral minitho-
racotomy. Three tumor cell types were identified: epithelial, 
biphasic, and sarcomatous.
Eight hundred sixty-two patients received medical treat-
ment alone, consisting in either chemotherapy (n = 172) or 
best supportive care (n = 690); 503 patients received surgical 
treatment with or without chemotherapy, consisting in either 
P/D (n = 202, 6 patients underwent only pleurectomy) or EPP 
(n = 301) according to their performance status, histology, and 
clinical staging of the disease. Before 2004, chemotherapy 
consisted of cisplatin and/or gemcitabine and after that date 
a combination of cisplatin and pemetrexed. Patients with his-
tologically confirmed nonsarcomatous MPM, younger than 
75 years, with a Eastern Cooperative Oncology Group per-
formance status of 0 to 1, and normal liver and renal function 
tests were evaluated for surgery with pulmonary function test-
ing, quantitative ventilation–perfusion scanning, echocardiog-
raphy, and computed tomographic (CT) scanning of the chest 
and abdomen. Additional imaging studies were performed as 
clinically indicated.
Patients were considered suitable candidates for mul-
timodality therapy with EPP if the predicted postoperative 
forced expiratory volume in 1 second was at least 1 liter, and 
echocardiography showed a grossly normal cardiac function 
and an ejection fraction of more than 45%, with an estimated 
normal pulmonary artery pressure. Surgical resectability was 
defined by tumor confined to one hemithorax without any 
evidence of metastatic disease, or invasion of the chest wall 
(preservation of extrapleural fat planes, absence of extra-
pleural soft-tissue masses, and absence of rib displacement 
or infiltration) or mediastinum (normal CT attenuation val-
ues of mediastinal content), or transdiaphragmatic extension 
(smooth diaphragmatic undersurface). The decision to per-
form EPP or P/D was based on the extent of the disease, with 
locally advanced MPM patients being treated mainly with 
EPP. EPP was defined as an en bloc resection of the pleura, 
lung, ipsilateral diaphragm, and pericardium; P/D was defined 
as an extrapleural dissection from the apex to the diaphragm; 
decortication of the lung was performed where the visceral 
pleura was macroscopically involved including the pulmonary 
fissures down to the pulmonary artery and pleural reflections 
if involved. The aim of surgery was to obtain a radical mac-
roscopic resection. Postoperatively, patients treated with P/D 
received adjuvant chemotherapy and/or radiotherapy. Since 
1999, after EPP, adjuvant chemo-radiation was carried out 
according to the scheme by Sugarbaker et al.5
Sixty-eight patients (19 in nonsurgical group, 46 in 
P/D group, and 3 in EPP group) were lost at follow-up. The 
remaining 1297 patients were followed up until death or for a 
minimum period of 1 year. Survival was measured from the 
date of surgical diagnosis; in the surgical groups (P/D and 
EPP groups), the survival was also analyzed from the data of 
surgery. In the surgical group, the median interval between 
diagnosis and surgery was 2.8 months (range, 0.5–4 months).
Patients were followed up with a chest CT arranged 
every 6 months to monitor response to treatment or disease 
progression. Those relapsing after multimodality therapy 
were offered second-line treatment: combination chemother-
apy with pemetrexed and cisplatin or single-agent vinorel-
bine. Radiotherapy was offered as a palliative measure when 
patients were diagnosed with relapse.
The following characteristics were analyzed: age, sex, 
asbestos exposure, smoking history, performance status, his-
tology, and treatment options (palliative treatment, chemo-
therapy, or surgery), dividing patients undergone EPP or PD 
and chemotherapeutic regimens with or without pemetrexed.
Univariate and multivariate analyses were performed, 
using the Cox regression model. A two-sided test was used 
at 5% level of significance. The univariate and multivariate 
analyses were limited to patients (n = 1227) in whom infor-
mation on overall survival (OS) was available. Survival func-
tions were estimated using the Kaplan–Meier technique. The 
subgroup of covariates that best discriminated the prognosis 
was obtained by means of the classification and regression 
tree (CART) method. Statistical analysis was performed using 
SAS version 9.2 (SAS Institute, Inc., Cary, NC); the CART 
method was applied using R version 2.15.1; the survival plots 
were performed using STATA version 12.1.
RESULTS
A total of 1365 consecutive patients were enrolled in the 
study. Most of the patients were male (68.1%) and the most 
frequent tumor cell type was the epithelial (57.9%); patient 
characteristics were summarized in Table 1. Clinical and path-
ological staging were reported in Table 1; the data showed that 
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in both surgical groups, there was a shift of patients with stage 
I and II to stage III and IV between clinical and pathological 
staging: in the P/D group the pathological staging showed an 
increase of 15% of stage III and IV and in the EPP group an 
increase of 42% of pathological stage III and IV. Five hun-
dred three patients underwent surgical resection by either P/D 
(n = 202) or EPP (n = 301). The 30- and 90-day crude mortal-
ity rate was 2.6% and 6% after P/D, and 4.1% and 6.9% after 
EPP, respectively (χ2
1df
 test for difference at 30-day mortal-
ity = 0.707, p = 0.401; χ2
1df
 test for 90-day mortality = 0.136, 
p = 0.713). In the P/D group, 21 patients (10.4%) experienced 
postoperative complications: atrial fibrillation (n = 9), pro-
longed air leak for more than 7 days (n = 5), bleeding (n = 3; 
1 patient required reoperation), myocardial infarction (n = 2), 
controlateral pleural effusion (n = 1), and paraplegia (n = 1).
In the EPP group, 65 patients (21.6%) developed post-
operative complications: atrial fibrillation (n = 32), bleed-
ing (n = 13; 4 patients required reoperation), chest infection 
(n = 4), bronco-pleural fistula (n = 3), pulmonary embolism 
(n = 3; 2 fatal), displacement of diaphragmatic prosthesis 
with herniation (n = 3; 1 patient required reoperation), respi-
ratory insufficiency (n = 2), deep vein thrombosis (n = 2), 
acute respiratory distress syndrome (n = 1), cerebral ischemia 
(n = 1), and wound infection (n = 1). The major perioperative 
morbidity was 7.6%. There was a statistically significant dif-
ference in the postoperative complication rate between P/D 
and EPP ((χ2
1df
 = 10.695; p < 0.001).
In the P/D group, 159 patients (78.7%) received chemo-
therapy, but only 13 (6.4%) received adjuvant radiotherapy. In 
the EPP group, 206 patients (68.4%) received chemotherapy 
and 149 patients (49.5%) received also radiotherapy. There 
was a statistical difference in the number of patients who were 
able to receive chemotherapy between the two surgical groups 
(χ2
1df
 = 6.409; p = 0.014).
At the time of analysis, the median duration of obser-
vation was 6.7 years (range, 0.1–14.8). Two hundred thirty 
patients (17.7%) were alive. Five hundred twenty-two patients 
pN
  N0 — 89 (81.7) 169 (57.1)
  N1 — 9 (8.3) 38 (12.8)
  N2 — 11 (10.1) 89 (30.1)
  Unknown 93 (46.0) 5 (1.7)
Pathological stage
  I — 19 (14.4) 11 (3.7)
  II — 47 (35.6) 62 (20.9)
  III — 46 (34.8) 206 (69.4)
  IV — 20 (15.2) 18 (6.1)
  Unknown — 70 (34.7) 4 (1.3)
P/D, pleurectomy/decortication; EPP, extrapleural pneumonectomy; FEV1, 
forced expiratory volume in 1 second; COPD, chronic obstructive pulmonary disease; 





n = 862 (%)
P/D Group
n = 202 (%)
EPP Group






n = 862 (%)
P/D Group
n = 202 (%)
EPP Group
n = 301 (%)
Age, yr, median (range) 67.0 (25–95) 62.5 (30–87) 58.7 (33–78)
  <70 509 (59.0) 162 (80.2) 287 (95.3)
  ≥70 353 (41.0) 40 (19.8) 14 (4.7)
Sex
  Male 570 (66.1) 149 (73.8) 225 (74.7)
  Female 292 (33.9) 53 (26.2) 76 (25.3)
Smoking
  Smoker 237 (48.0) 97 (49.0) 147 (51.4)
  Nonsmoker 257 (52.0) 101 (51.0) 139 (48.6)
  Unknown 368 (42.7) 4 (2.0) 15 (5.0)
Asbestos exposure
  No 207 (46.8) 107 (69.5) 96 (49.7)
  Yes 235 (53.2) 47 (30.5) 97 (50.3)
  Unknown 420 (48.7) 48 (23.8) 108 (35.9)
COPD
  No 51 (92.7) 116 (94.3) 166 (97.6)
  Yes 4 (7.3) 7 (5.7) 4 (2.4)
  Unknown 807 (93.6) 79 (39.1) 131 (43.5)
CAD
  No 53 (96.4) 165 (94.3) 236 (94.4)
  Yes 2 (3.6) 10 (5.7) 14 (5.6)
  Unknown 807 (93.6) 27 (13.4) 51 (16.9)
FEV1, liter, median (range)
  <60% 11 (27.5) 27 (28.7) 20 (18.5)
  ≥60% 29 (72.5) 67 (71.3) 88 (81.5)
  Unknown 822 (95.4) 108 (53.5) 193 (64.1)
Chemotherapy
  No 658 (79.3) 43 (21.3) 35 (14.5)
  Yes 172 (20.7) 159 (78.7) 206 (85.5)
  Unknown 32 (3.7) 0 (0) 60 (19.9)
Clinical stage
  I 34 (14.9) 25 (25.3) 23 (12.5)
  II 80 (35.1) 39 (39.4) 100 (54.3)
  III 68 (29.8) 34 (34.3) 61 (33.2)
  IV 46 (20.2) 1 (1.0) 0 (0)
  Unknown 634 (73.5) 103 (51.0) 117 (38.9)
Histology
  Epithelial 385 (44.7) 147 (77.0) 258 (86.6)
  Biphasic 105 (12.2) 40 (20.9) 40 (13.4)
  Sarcomatoid 60 (7) 4 (2.1) 0 (0)
  Unknown 312 (36.2) 11 (5.4) 3 (1.0)
pT
  T1 — 19 (14.4) 13 (4.4)
  T2 — 50 (37.9) 84 (28.4)
  T3 — 43 (32.6) 181 (61.1)
  T4 — 20 (15.2) 18 (6.1)
  Unknown 70 (34.7) 5 (1.7)
(Continued)
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(40.3%) died within 1 year. The duration of observation for 
patients living more than 1 year was 6.7 years (range, 1.1–
14.8). Twenty-six patients (3.1%) in the nonsurgical group 
are still alive, compared with 23 patients (14.8%) in the P/D 
group and 43 (14.4%) in EPP group. Median survival of the 
entire study population was 14.5 months (95% CI, 13.5–15.2). 
Patients who received palliative treatment or chemotherapy 
alone had an overall median survival of 11.7 months (range, 
10.5–12.5 months), a 2- and 5-year survival rate of 19% (95% 
CI, 0.16–0.22) and 4% (95% CI, 0.03–0.05).
Patients who underwent P/D had a median survival of 
20.5 months (95% CI, 18.2–23.1) and a 2- and 5-year sur-
vival rate of 40% (95% CI, 0.32–0.48) and 10% (95% CI, 
0.06–0.16). Patients who underwent EPP had a median sur-
vival of 18.8 months (95% CI, 17.2–20.9), and a 2- and 5-year 
survival rate of 37% (95% CI, 0.31–0.42) and 12% (95% CI, 
0.07–0.17). Median survival of patients undergoing surgical 
resection with adjuvant therapy was significantly longer than 
that of patients undergoing chemotherapy only (19.8 versus 
11.7 months; χ2
2df
 = 74.541; p < 0.0001; Fig. 1).
Analyzing the three groups before and after the intro-
duction of pemetrexed as first-line chemotherapeutic agent 
for MPM, there was an improvement in survival after the 
introduction of pemetrexed in all three groups: in the nonsur-
gical group, the median survival increased from 10.9 (95% 
CI, 9.6–11.9) to 15.3 (95% CI, 13.2–17.0) months, in the 
PD group from 19.5 (95% CI, 16.0–22.2) to 23 (95% CI, 
19.5–28.4) months and in the EPP group from 17.2 (95% CI, 
15.2–18.8) to 23.3 (95% CI, 19.0–27.0) months; although the 
prognosis for each group improved before and after the intro-
duction of pemetrexed, it was not detected a statistically sig-
nificant impact of treatment on the OS hazard ratio before and 
after the introduction of pemetrexed (χ2
2df
 = 2.198; p = 0.333).
Moreover, analyzing the survival stage by stage in the 
three groups of patients, no statistically significant interaction 
was detected between the type of treatment and the clinical 
stages in terms of overall survival (χ2
5df
 = 2.201; p = 0.821). 
Among the pathological stages, a statistically significant inter-
action was detected between the surgical groups, and the path-
ological stage IV median OS was 28.0 (95% CI, 10.5–73.7) 
months and 10.9 (95% CI, 5.3–13.6) months for EPP and PD 
groups, respectively (χ2
1df
 = 9.765; p = 0.002); however, this 
result should be considered with extreme caution because of 
the large amount of missing data and the small sample size of 
stage IV patients (17 patients in EPP group and 20 patients 
in PD group; see Supplemental Figures 1–7, Supplemental 
Digital Content 2, http://links.lww.com/JTO/A518).
At univariate analysis, factors that predicted a better 
prognosis were age, epithelioid histology, chemotherapy, and 
surgical treatment (Table 2). The cutoff that better discriminated 
the prognosis for age was 70 years (hazard ratio, 1.63; 95% CI, 
1.43–1.86). There was no correlation with sex and survival. The 
worse prognosis was correlated to the sarcomatoid subtype. 
Chemotherapy increased the survival both in surgical and non-
surgical patients. Surgery reduced the risk of death compared 
with chemotherapy or palliative treatment alone.
According to multivariate analysis (Table 3), age, histol-
ogy, and surgical treatment were independent prognostic factors 
associated with survival. Patients younger than 70 years, with 
epithelioid mesothelioma, who received chemotherapy, had the 
best prognosis in all surgical and nonsurgical groups.
When the impact of surgery was evaluated in the subset 
of patients with best prognosis (younger than 70 years, with 
epithelioid mesothelioma who had received chemotherapy; 
n = 313), P/D showed the best median survival (24.6 months; 
95% CI, 20.5–29.0), followed by EPP (20.9 months; 95% CI, 
17.6–23.4 months) and nonsurgical patients (18.6 months; 
95% CI, 16.2–24.9). However, this difference was not statisti-
cally significant (χ2
2df
 = 1.036; p = 0.596; Fig. 2).
DISCUSSION
The best treatment option for patients with MPM 





Variable HR 95% CI p
Sex
  Male 1 — 0.309
  Female 0.94 0.83–1.06
Age (yr) 1.02 1.01–1.03 <0.001
Histology
  Epithelioid 1 <0.001
  Biphasic 1.58 1.33–1.87
  Sarcomatoid 1.98 1.52–2.58
Chemotherapy
  No 1 <0.001
  Yes 0.59 0.52–0.67
Treatment
  Nonsurgical 1 <0.001
  EPP 0.58 0.50–0.67
  P/D 0.57 0.47–0.69
Data of potential prognostic factors are expressed in terms of HR and 95% CI.
HR, hazard ratio; CI, confidence interval; EPP, extrapleural pneumonectomy; P/D, 
pleurectomy/decortications.
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are lacking. An accurate clinical staging system would be 
extremely important in assessing the benefit of different treat-
ments. However, clinical evaluation of tumor extent remains 
poor and the high proportion of understaged patients makes 
very difficult to select optimal candidates for multimodality 
treatment or chemotherapy alone.
If pemetrexed-based chemotherapy is generally considered 
the standard of care for patients with MPM, the role of surgery 
remains questionable. Moreover, there is a debate among sur-
geons regarding the role of EPP versus P/D in the multimodal-
ity treatment. The aim of surgery is to achieve a macroscopic 
complete resection to improve the ultimate response to chemo 
and/or radiotherapy. EPP is performed with an en bloc resection 
of mediastinal and thoracic parietal pleura, diaphragm, pericar-
dium, and lung. EPP allows higher dose of radiotherapy reducing 
the local recurrence rate, but this operation leaves patients with 
major impairment of the postoperative quality of life.12
EPP gained wide acceptance after the publications of 
studies by Sugarbaker et al.5 and Rusch et al.,13 showing a favor-
able outcome in patients with epithelioid histology. The expe-
riences accumulated in patients with best prognostic factors, 
receiving chemotherapy followed by EPP and adjuvant radio-
therapy, showed a 5-year survival rate of more than 40%.14,15 
Although EPP-related mortality is now less than 8% in large-
volume centers, less than 60% of the patients complete trimo-
dality treatment because of death or major complications.16
In our series, in the EPP group, the overall and major 
perioperative morbidity were 21.6% and 7.6%, respectively, 
much lower than the overall morbidity rate of 50% to 68%, 
and the major complication rate of 23% to 54% reported in 
several series.5,9,14,15 In our EPP group, the crude perioperative 
mortality at 30 and 90 days was 4.1% and 6.9%, respectively, 
and the overall median survival was 18.8 months, very similar 
to the results published in the literature, ranging from 12 to 25 
months. Most of these literature series are on the basis of ret-
rospective analysis, with only four prospective studies involv-
ing patients treated with trimodality therapy and EPP, where 
the median survival ranged from 16.8 to 25.5 months and the 
30-day mortality from 0% to 5%.14,17–19 These data suggest that 
EPP can be performed with an acceptable perioperative mor-
bidity and mortality rate in specialized centers.
P/D has long been used in patients with MPM. The P/D 
is performed removing the visceral and parietal pleura sparing 
the lung parenchyma. This translates into lower postoperative 
morbidity and mortality, and a better postoperative quality of 
life.12 In 1976, Wanebo et al.20 reported a median survival of 
21 months after pleurectomy, adjuvant radiotherapy, and sys-
temic chemotherapy. More recently, similar outcomes have 
been reported in patients treated with P/D and adjuvant radio-
therapy plus chemotherapy.21–23 In a systematic review, Teh 
et al.24 showed an operative mortality ranging from 0% to 4% 
and a 3-year survival of 0% to 18% after lung-sparing extir-
pative surgery. In our series, survival in the entire population 
was significantly better after surgery and chemotherapy than 
chemotherapy alone; after P/D, the survival was even better 
than after EPP, with a median survival of 20.5 months, a post-
operative complication rate of 10.4%, and a 30- and 90-day 
mortality rate of 2.6% and 6%, respectively.
Recently, other authors have reported interesting 
results after P/D associated with photodynamic therapy25 or 
hyperthermic povidone lavage26 with a median survival of 
24 to 30 months, better than patients who underwent EPP. 
 Lang-Lazdunski et al. have shown that survival after incom-
plete macroscopic resection by P/D is similar to the one of 
complete macroscopic resection by EPP.
In the present multicenter study, the decision to perform 
EPP or P/D was left to the individual surgeon, after careful assess-
ment of patient’s operative risk, tumor staging, and the possibility 
to remove all macroscopic tumor. We confirm the results reported 
by other studies showing similar survival after P/D or EPP with 
a lower morbidity and mortality after P/D. In our series after the 
introduction of pemetrexed, our patients showed an improvement 
of survival in all three groups; surgical patients (P/D and EPP) 
had a better prognosis than patients undergone palliative treat-
ment or chemotherapy alone, also in the stage by stage analysis, 
TABLE 3.  Multivariate Survival Analysis (N = 1227)
Variable HR 95% CI p
Age (yr) 1.01 1.01–1.02 <0.001
Histology
  Epithelioid 1 — <0.001
  Biphasic 1.42 1.18–1.71
  Sarcomatoid 1.99 1.51–2.63
Chemotherapy
  No 1 — 0.309
  Yes 0.91 0.77–1.09
Treatment
  Nonsurgical 1 — 0.001
  EPP 0.77 0.64–0.93
  P/D 0.69 0.55–0.86
Data of potential prognostic factors are expressed in terms of HR and 95% CI.
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but this difference lost most of its relevance when other prog-
nostic factors were taken into account. Moreover, the power of 
each statistical test is drastically reduced in stage by stage analy-
sis, because of the large amount of missing data and the small 
sample size of pathological stage IV patients (only 37 patients). 
The variability of MPM populations points out the importance 
of analyzing surgical data after proper adjustment for clinical 
prognostic factors that could affect survival, such as age, histol-
ogy, and staging. In our study, the multivariate analysis showed 
that age and histology were independent prognostic factors for 
survival, instead there was no impact of clinical stage and sex. 
Three large trials had focused on prognostic factors.27–30 Curran 
et al. showed that sex had only a moderate significance in the 
multivariate model, in other series female sex was a significant 
positive prognostic factor for survival. This uncertainty could 
be justified by the limited number of females with MPM affect-
ing the prognostic importance of this variable. Among the tumor 
prognostic factors, the most important was the histology. All tri-
als confirmed the statistical significance of histology, but not of 
the age. Instead, age was confirmed to be a significant prognostic 
factor in the series published by Antman.27–31 Among the tumor 
prognostic factors, the most important was the histology.31
When our analysis was restricted to the subjects with 
positive prognostic factors, patients showed a similar sur-
vival if they had received chemotherapy alone, P/D, or EPP. 
Overall, our data indicate that survival might be slightly better 
for  surgical patients, with similar outcome for P/D and EPP.
Also, Flores et al.10 reported that there is still lack of 
evidence on the real impact of surgery on survival in patients 
with MPM, showing that other factors influence survival. 
These data suggest that surgical approach may select a patient 
population already destined to have a good prognosis even 
without surgical treatment.
Our series has serious limitations because of its retro-
spective nature and different therapeutic approaches among the 
various centers, with biases related also to the different selection 
criteria and the length of the study period. Whereas, it benefits 
from including a large number of patients. Our analysis was also 
limited by the quality of comorbidity data, particularly for the 
nonsurgical group.
In the literature, there is only one randomized study, the 
MARS trial, that did not show any advantage of EPP versus 
chemotherapy alone.11 This study was not designed to test a 
survival benefit of multimodality treatment compared with che-
motherapy and elicited a strong criticism in the medical com-
munity, related to important potential biases in the study design, 
analysis, and interpretation.32 As a matter of fact, the trial was 
an underpowered feasibility study and enrolled a very limited 
number of patients (50 randomized), and only a fraction of 
them received the planned therapy; moreover, in the EPP group, 
the postoperative mortality was 18%, higher than the mortality 
rate reported in the literature. For all these reasons, the present 
study, using multivariable analysis, adjusted for possible con-
founders, on a large population of patients, provides the next 
best level of evidence.
As a randomized trial of EPP versus P/D is unlikely to be 
performed, because of the existing data on survival and quality 
of life after P/D and EPP, it seems that future research efforts 
should concentrate on the launch of a large multicenter trial 
comparing P/D after induction chemotherapy versus chemo-
therapy alone in patients with favorable prognostic factors. To 
obtain meaningful results, the manner in which surgeons per-
form P/D needs to be standardized, before testing the impact of 
P/D versus no-P/D on survival and quality of life. This study 
could address the fundamental question on the real efficacy of 
cytoreductive surgery in improving the outcome and survival 
of patients with resectable malignant mesothelioma.
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